Cơ Chế Tác Dụng :
Alferminogene Tadenovec is Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard cardiac infusion catheter.
Alferminogene tadenovec holds the potential to promote a disease-modifying improvement by leveraging the body’s natural healing processes in response to myocardia ischemia (insufficient blood flow and myocardial oxygen supply). Angiogenesis, the growth of new collateral blood vessels, is a natural biologic response to repeated myocardial ischemia. These newly formed vessels provide alternate routes of blood flow and oxygen delivery to parts of the patient’s heart downstream from a blockage in a coronary artery. In many patients however, including those with recurrent angina, coronary collateral vessel formation is insufficient to meet the heart’s needs during stress. Currently available anti-anginal drugs, which may provide symptomatic relief, are generally designed to alter the oxygen demand of the heart muscle or dilate vessels to temporarily relieve angina. Alferminogene tadenovec is designed to promote the heart’s natural response of collateral growth and to increase blood flow in the microcirculation.
Chỉ Định :
Investigated for use/treatment in angina, coronary artery disease, and heart disease.